Telemedicine on Metabolic Control in Type 1 Diabetes Mellitus Andalusian Patients (PLATEDIAN)
Telemedicine on Metabolic Control in Type 1 Diabetes Mellitus Andalusian Patients (PLATEDIAN)
To assess the effect of a 6-month telemedicine program (DiabeTIC) in patients with type 1
 diabetes mellitus (DM1) and regular metabolic control (HbA1c <8%) in multi-dose insulin
 treatment (MDI) measured HbA1c vs. conventional medical care.
The substitution of face-to-face visits for telematics visits has a similar effect on
 glycemic control (measured by HbA1c) in patients with DM1 treated with multiple daily doses
 of insulin (MDI) and regular metabolic control (HbA1c <8 %). It even saves costs and
 consumption of health resources, and improves the quality of life and satisfaction of
 subjects with DM1

 To evaluate the effect of a 6-month Diabetic platform on telemedicine in patients with DM1
 and regular metabolic control (HbA1c <8%) on MDI treatment in the following parameters:

 A) Glycemic control: Mean glycemia, number of mild hypoglycemia / week, number of severe
 hypoglycemia / 6 months, number of hyperglycemia greater than 250mg / dl / week, number of
 episodes of ketosis / 6 months, number of episodes of ketoacidosis / 6meses , Number of
 hospital admissions due to glycemic decompensation / 6 months.

 B) Glycemic variability: Standard deviation, mean amplitude of glycemic excursions (MAGE).

 C) Fear of hypoglycemia: scale FH-15. D) Quality of life: Diabetes Quality of Life
 Questionnaire (DQoL). E) Stress: DDS questionnaire.

 F) Costs and consumption of health resources:

 -Cost-effectiveness (HbA1C)
Inclusion Criteria:

 -  Patients with DM1 over 2 years of evolution.

 -  Age ≥18 and <65 years.

 -  HbA1c prior to inclusion of the study <8% (the measure being valid in the month prior
 to inclusion in the study)

 -  Intensive insulin therapy with basal-bolus MDI.

 -  Patients living in Andalusian

 -  Patients candidates for telemonitoring.

 -  Patients who have received written informed consent.

 Exclusion Criteria:

 -  Treatment with ISCI.

 -  Chronic kidney disease, liver disease, thyroid dysfunction (except hypothyroidism
 correctly treated and controlled).

 -  Pregnancy or pregnancy planning.

 -  Diabetes mellitus type 2.

 -  Severe psychological disturbances.

 -  Absence of collaboration (informed consent).

 -  Patients who are participating in other clinical studies.